Drugs / ACE Reno
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07187713 | Sep 2025 → Aug 2026 overdue | autoimmune disease, diabetic kidney disease, end stage renal failure, hypertensive nephropathy +1 | Ace Cells Lab Limited | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE Reno | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07187713 ↗ |
| Modality | Peptide | “No genetic material is present; formulation is peptide-based only.” NCT07187713 ↗ |
| Route | Other | “1 ml sublingual 4 times daily for 12 weeks” NCT07187713 ↗ |